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ABSTRACT The N-ter~ninal20 residues of 13 heavy iJD-
JDuh~glohulin chains froiD ~nyelo1na proteins of the 
BALB/c !Douse are coiDpared with the saJDe residues of 
15 other heavy chains described in the literature. Sixieen 
of 28 sequences are different froiD one another. These pro-
teins fall into four 1najor sets, with 18 ofthe'proteins in the 
largest set being further divisible into at least five subsets. 
This pattern of diversity suggests there are at least eight 
gerJD line genes coding for the variable regions of !Douse 
heavy chain. Many of the iiDJDunoglobulins froiD which 
these heavy chains are derived exhibit binding acti~ty for 
various haptens. The differing hapten specificities are 
closely correlated with distinct pri1nary a~nino-acid se-
quences. 
An understanding of the genetic mechanism responsible. for 
antibody diversity is one of the most intriguing problems in 
modern immunology, for its resolution may provide insights 
into the problems of information storage and expression in 
other complex systems (1, 2). Two alternative hypotheses for 
antibody diversity have been proposed-the germ line theory 
suggests that diversity arises in antibody genes during the 
evolution of the species, whereas the somatic theories propose 
that antibody diversity is created anew during the devel~p­
ment of each individual by somatic mutation (1-3). Insights 
into the nature of this problem have come, in part, through the 
patterns observed from the detailed amino-acid sequence 
analysis of homogeneous myeloma immunoglobuliriS .. The 
immunoglobulin molecule is comprised of two different 
polypeptidE)s, light and heavy chains (4). All immunoglobulin 
chains can be divided into two segments, the variable (V) and 
the constant (C) regions, which code, respectively, for the 
antigen-binding and the various effector functions of the 
antibody molecule (5). Th,ere are three families of immuno-
globulin genes, which are unlinked in the mammalian genome. 
Two code for light chains [lambda (>.) and kappa (K)] and the 
third codes for heavy chains (1). The V and C genes of a given 
family appear to be coded by separate germ line genes (6). 
Myeloma proteins from the· inbred BALB/c mouse have 
proven to be a fruitful system for the analysis of amino acid 
sequence patterns because tumors can be induced at will and 
are readily transplanted from one individual to a second (7). 
In addition, these inbred mice are presumably genetically 
homogeneous, in contradistinction to the genetic poly-
morphism present in most outbred populations such as 
humans and rabbits. 
Abbreviations: V and C, variable and constant regions of im-
munoglobulin chains. 
Two important patterns relevant to theories of antibody 
diversity have emerged from the sequence studies on myeloma 
proteins. First, the V regions from most inimunoglobulin 
families can differ so extensively that all immunologists agree 
that they are cOded by multiple germ line V genes. Thus, all 
theories of antibody diversity are inultigenic, the question at 
issue is how multigenic. Second, when the V regions from large 
numbers of myeloma light or heavy chains are compared, 
three to four sections of extreme sequence variability are 
noted, which are designated "hypervariable regions" (8, 9). 
X-ray crystallographic studies have established that antibody 
polyj>eptides fold so that hypervariable regions constitute the 
walls of the antigen-binding crevice (10, 11, 32). The presence 
of hypervariable regions that make up the antigen-binding 
site has divided somatic theories into two groups. Both agree 
that the total antibody diversity is coded in part by germ line 
V genes and in part by V genes somatically derived from the 
germ line by mutation and stepwise selection for superior an-
tigen binding sites. One class of somatic theories argues that 
the selection for somatic variants occurs predominantly, if not 
exclusively, in the hypervariable regions (2), whereas, a second 
group of somatic theories argues that somatic variation can 
·occur throughout the entire V region (3). 
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Previous studies from our laboratories have assessed the 
diversity present in myeloma proteins from the two light chain 
families of the BALB/c mouse,>. and/( (12-16). In this paper 
we extend these studies to include an analysis of the N-
terminal 20 amino-acid residue.S of 28 myeloma heavy chains 
derived from BALB/c mice. These sequences lie outside the 
hypervariable regions of the heavy chain and will, accordingly, 
place different constraints on the various theories of antibody 
diversiiy outlined above. 
METHODS AND RESULTS 
Molijle myeloma proteins were isolated from serum of tumor-
bearing BALB/c mice by immunoabsorption for those 
examples with known specificities; J558 and MOPC 104E on 
dextran B-13558-polyacrylamide gel (17), W3129 and W3434 
on Sephadex G-75, and S23 on dinitrophenyl (Dnp) Sepharose 
(18). J606 and Y5606 were precipitated from serum by dialysis 
against 0.01 M NHtHCOa (19). Y5476, Y2020, Y5444, 
W3082, and S176 were isolated by the methods described by 
Potter (20). The purified proteins were partially reduced and 
alkylated and heavy and light chains were separated as 
described by Bridges and Little (21). The heavy chains were 
desalted, lyophilized, and approximately 10 mg per run was 
loaded on the sequencer. 
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. Light 
Tumor lg Chain Activ-
Number Claas Type 1 5 10 15 20 ity 
~typeVBI EVQLQESOPSLVKPSQ TLSL 
M460 IgA • Dnp 
823 IgA c Dnp 
M3111" lgA A D 0 8 Dnp 
Prototype VBII EVQL QESGPELVKPOA8VKM 
J558 lgA A * • 1,3D 
MIME lgM A 1,3D 
PrOtotype VBIII EVKLLESGOOLVQP008LKL 
YM76 IgA L 
W3434 lgA c 1,6D 
W3i29 I &A --vr• • 1,6D c 
M173" lgA c P--L u 
H2020 lgA ·A -Q-V • u 
YM44 Ig02a A -M-V • u 
8U)Ii IgA c 1,60 
X24d IgA • 1,60 c 
X44d IgA 1,60 
T191d lgA 1,60 
j53gd IgA c 1,60 
Jld IgA 
--1------ 1,60 
Hs• lgA c --v R- PC 
Tl5° lgA --v R- PC 
8107" IgA --v R- PC 
M603" IgA c --v R- PC 
M167° IgA --.V¥ R- PC 
Y5606 lg03 )\ D-Q-V • z-- TMA 
M21Ab IgA D-Q-VQ M- u 
M406b lgA c ~ AM W3082 lgA c --E M- L 
J606 IgG3 --E M- L 
Prototype VBIV EVQLQZSGTVLARPG8SLKM 
8176 zilajor lgA A liAU 
8176 minor IgA A 5AU 
FIG. 1. N-termina.l sequences of BALB/c heaVy' chains. 
The_Qne letter code of Dayhoff (28) is: A, Ala.; B, Asx; C, Cys; D, 
Asp; E, Glu; F, Phe; G, Gly; H, His; I, De; K, Lys; L, Leu; M, 
Met; N,· Asn; P, Pro, Q, Gin; R, Arg; S; Ser; T, Thr; V, Val; W, 
Trp, X; ?; Y, Tyr; Z, Glx; lg indicates immunoglobulin; 
Dnp designates dinitrophenyl; 1,3D indicates a-1-+3 dextran; 
1,6D designates a-1-+6 dext~a.n; U indicates unknown specificity; 
L. dangna.tes levan; AM designates N-a.cetjrl-n-ma.nnosa.mine; 
1,6G iridica.tes P-1-+6 galactan; PC indicates phosphorylcholine; 
TMA designates trimethylamine; and 5AU is 5-a.cetylura.cil. 
• From reference 29. b Quoted in ref. 7 and represents sequences. 
derived froin a. single sequentor run (J. M. Kehoe and J. D. Capra., 
personal communication). • From 30. d From 31. • From 24: • in-
dicates uncertainty about amide or residue a.ssignment. M104E 
indicates MOPC 104E; M406 indicates MOPC 406; the remainder 
of the complete names for the proteins is given in ref. 16. 
Each chain was subjected to 20 steps of automated Edman 
degradation on an updated Beckman 890A protein sequeriator 
employing a standard Quadrol or DMBA _program. Samples 
were dried under N2 and converted to the phenylthiohy-
dantoin amino acids (PTH) by treatment with 1 M HCl-1 
mM ethanethiol for 10 min at 80°. Following extraction in 
ethylacetate, 5% of each sample was run on a Hewlett 
Pacla!.rd gas chromatograph equipped with dual glass 7.5% 
DC-560 columns. Glutamine-glutamic acid and asparagine-
aspartic acid were resolved by thin-layer chromatography on 
silica gel (benzene: acetic acid, 9: 1) or by silylation of the 
phenylthiohydantoin derivatives followed by gas chromatog-
raphy. The amino acids were then regenerated by hydrolySiSin 
hydriodic acid for 18 hr at 120° (22) and analyzed on a Dut-
rum D-500 amino-acid analyzer. Throughout these experi-
ments phenylthiohydantoin norleucine was added to the 
sequencer tubes prior to conversion, to normalize for any 
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TABLE 1. Percent homology between 17IOU86 and human 
prototype sequences for the N -terminal SO residues 
*MVBn MVBm MVBIV *HVBI HVBu HVBIII 
MVBI 65 45 55 40 65 45 
MVBn 60 75 70 50 60 
;t\IVBm 60 45 50 85 
MVBIV 55 40 60 
HVBI 40 50 
HVHu 50 
• MVBI and HVHI respectively denote the prototypes from 
mouse and human VB regions. The human prototype sequences 
are derived from the data. given in ref. 26 . 
losses due to handling. The methodologies uSed have been 
described in detail in a previous publication (16). Yields of 
approximately 50% of the theoretical values· were noted at 
step 1 and repetitive yields averaged 90% for all chains. 
DISCUSSION 
Selection of Proteins. The heavy chains used in this. analysis 
were generally selected because the iniinunoglobuij.ns from 
which they were derived exhibited specific binding for one or 
more haptens (Fig. 1). 
Patterns of DiverBity. The amino terminal20 residues of 13 
heavy chains are compared with 15 sequences taken from the 
literature (Fig. 1). Sixteen of the 28 sequences differ by one 
residue or more. By sequence homology, these sequences can 
be divided into four major sets, which contain, respectively, 
22, 3, 2, and 1 proteins. Prototype sequences can be derived 
for each of these sets by selecting the major residue alternative 
expressed at each position (Fig. 1) and these are respectively 
designated prototypes VHIII, VHI, VHn, and VHiv,§ The four 
prototype sequences differ from one another by 25-55% of 
their residues (Table 1). Prototype set VHm can be broken 
down into at least four subsets that are defined by two or more 
linked residues. For example, the heavy chains from W3082 
and J606 have a glutamic acid at position 5 and a methionine 
at position 18 that distinguish these proteins from the remain-
ing proteins of this set (Fig. 1). In this fashion, the heavy 
chains from H8, T15, 8107, M603, and M167 as well as Y5606 
and M21A can also be divided into two additional subsets by 
the presence of linked amino acids (Fig. 1). 
The variable region of the heavy chain (VH region) is about 
120 residueS in length and hence the N-terminal 20 residues 
represent about 1/e of the VH region. Accordingly, a rough 
§The largest set of heavy chains is designated VBm beca.uae 
the chains show the greatest homology with the human heavy 
chains belonging to the VBm subgroup (see ref. 26). We have 
refrained from uaing the term V region subgroup for two reasons. 
First, with the accumulation of large amounts of sequence data. it 
has become apparent that the definition of what constituteS a. 
subgroup is uncertain. For example, within many subgroups, 
additional groupingS are defined uaing sma.ller numbers of linked 
residues. Are these new groupings additional V region subgroups? 
Second,· the term V region subgroup has had the genetic implica-
tion that it is encoded by at least one germ line gene. Yet each of 
the theories of antibody diversity incorporates very different 
ideas about what types of sequence patterns define additional 
germ line V genes. Thua we feel the term su~oup is undefinable, 
has confuaiil.g genetic implications, and should be replaced by a. 
more neutral term such as "set." 
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FIG. 2. A genealogic tree of heavy chains from BALB/c myeloma proteins. This tree was constructed using only the N-terminal20 
residues. Many of the immunoglobulins from which these VH regions were derived bind to one or more haptens. These specificities are 
shown below the tumor number. Abbreviations: Dnp, dinitrophenyl; PC, phosphorylcholine; 1,6D, a-1-6 dextran; 1,3D, a-1-3 dex-
tran; L, Levan; TMA, trimethylamine (7). 
estimate of the number of amino-acid differences between two 
V H regions can be determined by multiplying the difference in 
diversity shown over the N-terminal20 residues by six (this is 
an underestimate because no hypervariable regions are 
included in this region). Thus, proteins in different sets will 
probably differ by 48 residues or more, whereas proteins within 
a set can, from this estimate, differ by as many as 24 or more 
residues. The only two nearly complete mouse V H sequences 
from different sets, M315 and T173, are consistent with the 
above analysis in that they differ by 10 residues in the first 20 
and by 62/104 residues and two sequence gaps. 
Theories of V Gene Diversity. A more sophisticated examina-
tion of these proteins can be carried out by a genealogic analy-
sis (1). The sequences within any set can be related to one 
another by an evolutionary tree which depicts the minimal 
number of genetic events (i.e., single base substitutions) 
required to generate this set of sequences from a single 
ancestral sequence (gene). This procedure permits a step by 
step analysis of the single base substitutions required to gen-
erate diversity in a given set of sequences. One can then ask 
what events are compatible only with germ line evolution and 
what events might be explained by somatic evolution. The 
genealogic analysis in Fig. 2 shows that the relationships of 
these sequences to one another are somewhat more complex at 
the nucleotide than at the protein level because certain single 
amino-acid differences are coded by two base substitutions. In 
spite of this, four distinct branches are noted on the genealogic 
tree, which correspond to the four sets of sequences described 
previously, Vm through VH1v. The Vm branch is divided into 
five or more sub-branches by the presence of linked nucleotide 
bases in certain of the sequences (e.g., T15-167-5444; 3082-
606; 5476-3129-J1; 2020-5606-M21A-406; and 173-see Fig. 2). 
Obviously additional data will be required (more and longer 
sequences) to more sharply delineate this genealogic tree, 
particularly with regard to the sub-branch structure of V Hill· 
The somatic theory which argues for somatic variation only 
in hypervariable regions (2) and the germ line theory would 
agree on the conclusiQns to be drawu from this genealogic ttee; 
namely, each of the V regions that differ from one another is 
coded by distinct germ line V genes that arose by gene duplica-
tion, sequence divergence (mutation, recombination, etc.) and 
selection during the evolution of the species. Thus both of 
these theories would agree that the diversity noted in these V H 
regions must be coded by at least 16 germ line VH genes. If, 
however, it is postulated that replacements in the N-tetminal 
20 residues result from somatic mutation and selection, two 
questions must be asked. First, how many single base substitu-
tions are reasonable to postulate during the somatic develop-
ment of a given lymphocyte line? Second, how many parallel 
(or identical) mutations may occur in lymphocyte lines in 
separate individuals? If soma~ic diversification occurs by 
ordinary random mutation followed by selection, then it 
would appear likely that relatively few (i.e., 1-5) mutations 
occur per lymphocyte line because of the need to select and 
expand out each mutant clone of lymphocytes (2), in addition, 
no selective forces adequate to explain significant parallel 
mutation have been postulated to occur somatically, thus each 
set of sequences with multiple linked residues is probably 
derived from a different germ line gene (2). Accordingly, from 
the viewpoint of random somatic mutation that can occur 
~ throughout the entire V gene, at least eight germ line V H genes 
must be postulated for this group of V H regions, one for each 
distinct branch and sub-branch of the genealogic tree. A dis-
cussion of other somatic theories is beyond the scope of this 
report. 
The mouse heavy chain sequences examined here appear to 
-exhibit less diversity than the mouse K family ·and far more 
diversity than the mouse X family. This generalization should 
be qualified, however, because most of these V H sequences 
were derived from immunoglobulins selected because they 
exhibited binding activity for various haptens. Thus, these 
heavy chains certainly constitute a selected subset of BALB/c 
heavy chain myeloma pool. The degree of selection that 
occurred in examining primarily V H regions derived from 
myeloma proteins with binding activity is entirely unknown. 
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It will be very important to analyze the diversity exhibited by , 
unselected V H regionS to obtain a more reliable estimate of the 
diversity present in the BALB/c pool of myeloma heavy 
chains. In addition, mouse _heavy chains blocked at their 
N-termini comprise about 78% of the normal serum immuno-
globulin (23). Thus it will he particularly valuable to. analyze 
the extent of diversity present in these blocked sequences. 
Normal Pooled MllUBe Heavy Chains Appear to be More 
Restricted in Sequence Than the Pool of Myeloma Heavy Chains. 
A recent study reports that normal pooled mouse heavy chains 
differ in two respects from the sequences reported here. First, 
as mentioned earlier, the normal mouse H chains have a 
blocked a-amino group in 78% of the proteins {23). Only one 
of 20 myeloma H chains we examined was blocked (HOPC-1). 
Second, the pool of unblocked mouse H chains obtained from 
the serum appeared to have a single residue at the 95% level 
at most of the N-terminal 28 positions. This is in striking 
contrast to the myeloma data we have reported here. For 
example, in the pool of myeloma heavy chains, aspartic acid is 
seen in 14% of the sequences at position 1; glutamine is seen in 
32% of the sequences at position 3; the alternatives at position 
5 are evenly spread among a number of residues. Thus, the 
myeloma pool of heavy chains reveals a heterogeneity not 
dej;ectable by sequencing the normal pool, because the my-
- eloma population, not surprisingly, expands individual 
sequences that are normally represented infrequently or not at 
all in the serum pool. Hence one must be cautious about draw-
ing conclusions concerning the nature and extent of V region 
diversity from studies on normal pooled sequences. 
- It appears that the myeloma immunoglobulins are them-
selves highly selected in that 5% or more of them bind to a few 
determinants (7). This is unexpected in view of the enormous 
functional heterogeneity of the normal immune response. 
Accordingly, both the normal and myeloma pools could be 
interpreted not to represent the true V region diversity that is 
coded in the BALB/c genome. 
One obvious difference between the myeloma pool and the 
normal serum pool is the fact that the artificial induction of 
myeloma proteins in BALB/c mice selects primarily IgA 
proteins, whereas the normal serum pool is mostly of the IgG 
type (7). Obviously, an analysis has yet to be carried out of the 
extent and nature of amino-acid sequence diversity in the V H 
regions associated with BALB/c 'Y heavy chains. In any case, a 
critical question arises. Are. the V H regions associated with C'Y 
regions distinct from those associated with c .. regions? If the 
V H regions from 'Y and a myeloma proteins are equally 
diverse, then the normal and myeloma heavy chain pools 
express the same family of germ-line V H genes. If the V H 
regions from 'Y myeloma proteins are less diverse than those 
from their a counterparts, then selection must occur in the 
association of certain germ-line V H genes with given CH genes. 
Some MllUBe VH Regions Are Similar to Their Human 
Counterpart&, Whereas Others Are Quite Distinct. A rough 
comparison of the similarity of mouse and human heavy chains 
at their N-termini can be made by comparing the prototype 
sequences of the mouse and human VH sets (Table 1). The 
mouse and human prototypes are quite distinct from one 
another (30-00%) apart from the mouse and human V Hill 
sequences (about 15% difference). The comparison of the 
single nearly complete human VHnr sequence (Nie) with two 
mouse VH regions (M173-39% and M315-61%) suggests that 
Mouse Myeloma Heavy Chains 4099 
the group of mouse sequences to which M173 belongs is more 
closely related to the human V Hill sequence& than other 
mouse V H regions are, although they are not as closely related 
as suggested by the N-terminal data. The fact that many 
mouse V H prototypes are as closely related to one another as to 
their human counterparts suggests that multiple V H genes 
existed in the mouse-human ancestor (Table 1). Thus some of 
the VH genes in human and mouse may have been derived 
from a common VH gene in the human-mouse ancestor, " 
whereas others appear to have diverged from distinct genes in 
this ancestor. The heterogeneity of the myeloma heavy chains 
at theN-terminus compared with their normal counterparts 
also suggests that from the analysis of normal pooled se-
quences it is not possible to conclude that species- or phyla-
genetically associated residues are coded by a major portion of 
the germ-line V genes. 'I 
Tlw Hapten Binding Properties of Certain Myeloma Proteins 
Appear to Correlate with TMir Heavy Chain Sequences. Six 
groups of myeloma proteins with binding activity for different 
haptens are shown in Fig. 1. The binding activity for a specific 
hapten appears to correlate with the sequence of the N-
terminal20 residues (Figs. 1 and 2). Indeed, each of the major 
branches on the genealogic tree with just a few sequences 
correlates with a single hapten binding activity (e.g., dinitro-
phenyl-VHr, a-1-3 dextran-VHn, and 5-acetyluracil-
VHrv). The binding specificities for heavy chains in the VHIII 
branch generally correspond to the linked sets of proteins or 
subbranches that occur within this branch (e.g., the phos-
phorylcholine and levan binding heavy chains). Other studies 
suggest that the correlation of specificity with distinct amino-
acid sequences is much greater with the heavy than with the 
light chain sequences {24). 
TM CorrelatUm of Particular Antigen Binding Specificities 
with Particular N-Terminal Sequences Suggest8 That Selectimt "" 
for Function Occurs Outside As Well As Witkin Hypervariable 
Segment8 of V Regions. This observation renders unlikely 
theories of antibody diversity that argue that special hyper-
mutational mechanisms operate only in the hypervariable 
regions o:r that the hypervariable regions are coded by separate 
episome-like genes which are integrated into a framework V 
gene. Clearly, mutation and selection occur through the entire 
V gene. The relative contributions of germ line versus somatic 
diversification to this process remain uncertain. 
Heavy Chains May Have a Precursor with Additional Resi-
dues at theN-Terminus. The amino-acid sequence analysis of 
8176 revealed a mixture of two sequences, probably identical 
to one another but for a single extra residue at theN-terminus 
(Fig. 1). A recent report has demonstrated that a myeloma 
light chain synthesized in vitro has an additional 1G--15 
residues on the N-terminus (25) which are, presumably, 
cleaved off by a post-translational event in vivo. Accordingly, 
we suggest that heavy chains also have a precursor form that is 
modified post-translationally. The presence of the normal 
heavy chain in this tumor product suggests that the extra 
N-terminal residue cannot be accounted for by a mutational 
event at the DNA level. 
'I Species- or phylogenetically associated residues are those found 
at a particular position in most of the serum immunoglobulin 
chains of one species and which are distinct from the homologous 
residues of a second species (23, 27). 
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Are There Any Differences in the Set of VH Regions Asso-
ciated with ~ As Compared to k Light Chains'! None of the 
heavy chains associated with~ chains has a lysine at position 
3, a residue found in the heavy chains associated with 18 of 21 
"type molecules (Fig. 1). Eight of nine heavy chains derived 
from ~ type molecules have glutamine at position 3. On the 
other hand, the VH regions from M315 and M460 as well as 
Y5606 and M21A are quite similar, yet in each case one mole-
cule is of the~ and the other of the "type. Obviously a great 
deal more sequence data must be available before conclusions 
can be drawn regarding V H associations with V,. and V « 
regions. 
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